The American Society of Hematology (ASH) has announced a prestigious lineup of awardees for its 2026 Annual Meeting and Exposition, slated for December in New Orleans. This year’s honorees represent towering figures in hematology, recognized for their exceptional contributions that span basic science, translational research, clinical innovation, mentorship, and equity in patient care. Their pioneering work continues to chart new frontiers in understanding hematologic diseases, ultimately transforming clinical paradigms and improving patient lives globally.
Elliott Vichinsky, MD, from UCSF Benioff Children’s Hospitals, receives the Wallace H. Coulter Award for Lifetime Achievement in Hematology for his groundbreaking research and clinical leadership in hemoglobinopathies such as sickle cell disease and thalassemia. Over four decades, Dr. Vichinsky has fundamentally redefined disease management approaches, influencing both clinical protocols and public health initiatives. His efforts notably include establishing California’s universal newborn screening program for hemoglobin disorders, a monumental step toward early detection and intervention that has significant epidemiological benefits.
Dr. Vichinsky’s research elucidated critical pathophysiological aspects of sickle cell disease, including the neurocognitive decline in asymptomatic patients and the complex etiology of acute chest syndrome—a primary contributor to mortality. His involvement with disease-modifying therapies such as L-glutamine and voxelotor represents substantial progress in altering disease trajectories by targeting oxidative stress and hemoglobin polymerization. Additionally, his pioneering prenatal treatment strategies for alpha thalassemia major highlight the innovative integration of fetal medicine into hematologic care.
The Roland B. Scott-Charles Drew Excellence in Equity Award is bestowed upon Leon Bernal-Mizrachi, MD, of Wake Forest University School of Medicine, for his tireless advocacy for diversity and access in hematology. With a focus on equity, Dr. Bernal-Mizrachi has launched initiatives like the ASH Ambassador Program to inspire historically underrepresented medical students toward hematology careers while emphasizing inclusive clinical trial recruitment strategies. His global outlook addresses disparities in hematologic care and catalyzes efforts to broaden the scientific and clinical community’s demographic representation.
The J. Evan Sadler Award for Mentorship recognizes Roy Silverstein, MD, of the Medical College of Wisconsin and Versiti Blood Research Institute, celebrated for his profound dedication to guiding early-career hematologists. Known for his expertise in platelet biology and vascular disease, Dr. Silverstein’s mentorship emphasizes accessible, personalized guidance conducive to fostering scientific creativity and clinical acumen. His mentorship style, characterized by frequent and meaningful engagement, has shaped the careers of numerous researchers and clinicians who are subsequently advancing hematology research and patient care worldwide.
Similarly, Laura De Castro, MD, of the University of Pittsburgh School of Medicine, is honored with the Bernard Forget Award for Mentorship, reflecting her deep commitment to nurturing emerging hematologists with a particular emphasis on sickle cell disease. Her mentorship philosophy is grounded in advocacy, ethical practice, and balanced professional development. Dr. De Castro’s early engagement in tutoring and mentorship within her community informs her holistic mentorship approach, which cultivates academic rigor and compassionate patient care.
Stella Chou, MD, from the Children’s Hospital of Philadelphia, is the recipient of the William Dameshek Prize for her transformative research in transfusion medicine, particularly concerning alloimmunization in sickle cell disease. Her pioneering identification of variant Rh antigens as key drivers of alloimmunization has advanced immunohematologic diagnostics and optimized transfusion safety protocols. As a leader in the development of hemoglobinopathy transfusion guidelines and innovative laboratory techniques, Dr. Chou’s work significantly reduces transfusion-related complications and enhances patient outcomes.
Benjamin Levine Ebert, MD, PhD, at the Dana-Farber Cancer Institute, wins the Janet Rowley Basic Science Medal for elucidating mechanisms underpinning blood malignancies. His seminal work characterizing thalidomide and its analogs’ molecular action revealed how these agents function as molecular glues to induce targeted protein degradation, revolutionizing treatment of multiple myeloma and certain myelodysplastic syndromes. Furthermore, Dr. Ebert’s elucidation of clonal hematopoiesis’ role in blood cancers and systemic inflammatory conditions advances our understanding of pre-malignant states and their broader health implications.
Andrew Roberts, MBBS, PhD, a physician-scientist and editor-in-chief of Blood, is awarded the Helen M. Ranney Clinical and Translational Science Medal for his trailblazing work on BH3 mimetics in hematologic malignancies. His research was crucial in validating BCL2 as a therapeutic target, laying the scientific foundation for venetoclax, the first BCL2 inhibitor approved by the FDA. Dr. Roberts’s leadership in clinical trials has expanded targeted therapy options for chronic lymphocytic leukemia and various lymphomas, marking a turning point in cancer therapeutics through precision medicine.
The Ernest Beutler Lecture and Prize honors two luminaries: Suzanne Cory, PhD, from the Walter and Eliza Hall Institute of Medical Research, and Marina Konopleva, MD, PhD, from Albert Einstein College of Medicine. Dr. Cory’s pioneering identification of BCL2 as a fundamental cell survival gene, along with her collaborators, catalyzed the development of BH3 mimetics. Dr. Konopleva’s translational efforts target BCL2 and BCLXL using small molecule inhibitors, characterizing resistance pathways and synergistic therapeutic combinations. Their combined research powerfully advanced targeted treatment paradigms for leukemia and lymphoma patients.
Scott Armstrong, MD, PhD, at the Dana-Farber Cancer Institute, is awarded the E. Donnall Thomas Lecture and Prize for his cutting-edge research on epigenetic and genetic mechanisms driving leukemogenesis. His studies unraveled the unique gene expression signatures of MLL (KMT2A) rearranged leukemias and elucidated the cells of origin for various leukemia subtypes. His translational work propelled the development of menin inhibitors, which have recently received FDA approval, representing a novel class of epigenetic-targeting agents that expand therapeutic strategies against genetically defined leukemias.
Dr. Peihua ‘Peggy’ Lu of Lu Daopei Medical Group will deliver the Ham-Wasserman Lecture, focusing on her innovative contributions to the development and clinical implementation of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies. Dr. Lu’s pioneering work in China established the country’s first CAR-T clinical trials, targeting genes such as CD19, CD22, BCMA, and CD7. Her efforts have been transformative, particularly her advancement of CD7-directed CAR-T treatments for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma, broadening the therapeutic reach of immunotherapy into highly challenging T-cell cancers and providing new hope for critically ill patients.
Collectively, these scholars epitomize the innovative spirit and clinical commitment driving hematology forward. Their seminal discoveries and unwavering dedication to mentorship, equity, and patient-centered research are reshaping the understanding of blood diseases, from molecular mechanisms to population health. The 2026 ASH Annual Meeting will undoubtedly spotlight these leaders’ trailblazing work, underscoring hematology’s profound impact on modern medicine and offering a glimpse into future breakthroughs that will continue to improve outcomes for patients worldwide.
Subject of Research: Advances in Hematology Including Hemoglobinopathies, Hematologic Malignancies, Transfusion Medicine, and Immunotherapy
Article Title: Transformative Innovations and Leadership Highlighted by ASH 2026 Awardees
News Publication Date: June 23, 2026
Web References:
- https://www.hematology.org/
- https://www.hematology.org/awards/honorific/wallace-coulter-award
- https://www.hematology.org/education/educators/ambassador-program
- https://ashpublications.org/journals
Keywords: Hematology, Sickle Cell Disease, Thalassemia, Blood Cancer, Leukemia, Lymphoma, BH3 Mimetics, BCL2 Inhibitors, CAR-T Therapy, Hemoglobinopathies, Clonal Hematopoiesis, Mentorship, Health Equity
